DNA interstrand crosslinks (ICLs) are critical lesions for the mammalian cell since they affect both DNA strands and block transcription and replication. The repair of ICLs in the mammalian cell involves components of different repair pathways such as nucleotide-excision repair and the double-strand break/homologous recombination repair pathways. However, the mechanistic details of mammalian ICL repair have not been fully delineated. We describe here the complete coding sequence and the genomic organization of hSNM1B, one of at least three human homologs of the Saccharomyces cerevisiae PSO2 gene. Depletion of hSNM1B by RNA interference rendered cells hypersensitive to ICL-inducing agents. This requirement for hSNM1B in the cellular response to ICL has been hypothesized before but never experimentally verified. In addition, siRNA knockdown of hSNM1B rendered cells sensitive to ionizing radiation, suggesting the possibility of hSNM1B involvement in homologous recombination repair of double-strand breaks arising as intermediates of ICL repair. Monoubiquitination of FANCD2, a key step in the FANC/BRCA pathway, is not affected in hSNM1B-depleted HeLa cells, indicating that hSNM1B is probably not a part of the Fanconi anemia core complex. Nonetheless, similarities in the phenotype of hSNM1B-depleted cells and cultured cells from patients suffering from Fanconi anemia make hSNM1B a candidate for one of the as yet unidentified Fanconi anemia genes not involved in monoubiquitination of FANCD2.
Introduction
Bifunctional chemical agents such as mitomycin C (MMC), cisplatin and cyclophosphamide are widely used as anticancer drugs. A number of different types of DNA damage can result from interaction between a given bifunctional agent and DNA. The most cytotoxic lesion generated is the DNA interstrand crosslink (ICL). The mechanisms of ICL processing within the mammalian cell are poorly understood, but there is clear evidence that repair of these lesions utilizes proteins from different DNA repair pathways. Summarizing data from several laboratories, McHugh et al. (2001) proposed a model for S-phase-dependent ICL repair, which includes components of the nucleotide-excision repair and the double-strand break (DSB)/homologous recombination repair pathways. In this model, the replication fork disintegrates when it approaches the site of an ICL due to torsional stress, followed by formation of a DSB. The endonuclease activity of the XPF-ERCC1 complex is responsible for incision of the DNA near the ICL. Recombination events can occur across the unhooked ICL-containing strand, which can then be excised and filled in (McHugh et al., 2001) . Little is known about the genes involved in the homologous recombinational steps of ICL repair, but the fact that several genes of the homologous recombination repair pathway for DSBs confer sensitivity to ICL when mutated in rodent or human cells suggests a connection between DSB and ICL repair (Caldecott and Jeggo, 1991; Essers et al., 1997; Patel et al., 1998; Tutt et al., 1999; Moynahan et al., 2001) .
Sensitivity to ICL is a feature of Fanconi anemia (FA), a rare, autosomal recessive, inherited disorder, characterized by congenital defects, bone marrow failure and an increased incidence of cancer (Joenje and Patel, 2001; D'Andrea and Grompe, 2003) . Cells derived from FA patients are characterized by chromosomal instability and hypersensitivity to ICL-inducing agents and, in at least some cases, to ionizing radiation (IR) (Carreau et al., 1999; Garcia-Higuera et al., 2001; Gatti, 2001; Digweed et al., 2002) . The disease has a high degree of heterogeneity, with 11 known complementation groups (FA-A, B, C, D1, D2, E, F, G, I, J and K) (Levitus et al., 2003) and eight genes (FANCA, C, D1/BRCA2, D2, E, F, G, L) cloned thus far (Strathdee et al., 1992; Lo Len Foe et al., 1996 ; The Fanconi anaemia/breast cancer Consortium, 1996; de Winter et al., 1998 de Winter et al., , 2000a Timmers et al., 2001; Howlett et al., 2002; Meetei et al., 2003) . Most of the FA proteins associate in the FA core complex, which is required for the monoubiquitination of FANCD2, resulting in localization of FANCD2 in nuclear foci containing BRCA1 and BRCA2/FANCD1. The identification of BRCA2 as an FA gene and its function within the FA pathway are consistent with a role for the FA proteins in homologous recombination.
Investigation of DNA repair processes in lower organisms such as Escherichia coli or Saccharomyces cerevisiae has facilitated the understanding of related processes in mammalian cells in the past, often based on identification of human genes displaying sequence similarity to genes with known functions from lower model organisms. In order to better understand the repair of DNA lesions induced by treatment with the combination of psoralen and UVA (PUVA) in yeast, which includes formation of ICLs, numerous PSO mutants have been isolated on the basis of their hypersensitivity to this mutagen reviewed in Brendel et al., 2003) . Among these, pso2 mutants, which are allelic to snm1 mutants, show a specific sensitivity to ICL-inducing agents (Cassier et al., 1980; Henriques and Moustacchi, 1980; Cassier-Chauvat and Moustacchi, 1988) . The PSO2 gene is assumed to be involved in a late step of ICL repair, since mutant cells are proficient in creating the initial incision near ICLs necessary for their repair. However, the subsequent step, reconstitution of highmolecular-weight DNA, is defective (MaganaSchwencke et al., 1982; Wilborn and Brendel, 1989) . Identification and characterization of the 76 kDa pso2 protein revealed a putative zinc-finger motif and a nuclear localization signal (Richter et al., 1992) , suggesting interaction with nuclear DNA but the exact function of pso2 remains to be elucidated.
The human KIAA0086/hSNM1 gene was the first putative mammalian PSO2/SNM1 homolog identified (Nagase et al., 1995; Demuth and Digweed, 1998) . Mouse embryonic stem (ES) cells with disrupted mSNM1 display a twofold increase in their sensitivity to MMC, but not to other DNA crosslinking agents (Dronkert et al., 2000) . Richie et al. (2002) characterized the subcellular distribution of hSNM1 using indirect immunofluorescence. Exclusively nuclear expression was observed, with three different patterns, either diffusely distributed, localized within multiple punctate foci or forming one or two larger bodies. Treatment with IR or MMC resulted in an increased number of nuclei with multiple foci, and a concomitant decrease in the number of large body-containing nuclei. In addition, hSNM1 colocalized in a DNA damage-independent manner with 53BP1, a protein that plays a role in the cellular response to IR, although the functional significance of this finding was unclear (Richie et al., 2002) .
Four additional sequences with similarity to the yeast PSO2 gene have been reported: hSNM1C, also known as ARTEMIS, a partial sequence of hSNM1B (Dronkert et al., 2000) , and the more distantly related ELAC2 (Tavtigian et al., 2001 ) and CPSF73 (Jenny et al., 1996) . The sequence similarity between the PSO2 gene and these mammalian proteins derives largely from a shared metallo-b-lactamase domain, which is predicted to play a role in DNA and RNA metabolism (Ma et al., 2002) . Mutations in ARTEMIS have been found in a subset of patients with a severe combined immunodeficiency syndrome associated with radiosensitivity (RS-SCID) (Moshous et al., 2001) . Functional analysis of the ARTEMIS protein revealed its involvement in DNA overhang processing and opening of DNA hairpins generated during nonhomologous end joining (NHEJ) and V(D)J recombination (Ma et al., 2002) . ELAC2 is reported as a putative prostate cancer susceptibility gene (Tavtigian et al., 2001) and CPSF73 is involved in mRNA cleavage and polyadenylation (Jenny et al., 1996) . The hSNM1B gene has not been fully characterized at the sequence level, and its function is unknown.
Based on sequence similarity between yeast PSO2 and human SNM1B, we have tested the hypothesis that hSNM1B is involved in the cellular response to ICL. In our studies, depletion of hSNM1B by siRNA treatment conferred significant sensitivity to ICL-inducing agents and, in contrast to yeast pso2 mutants, to IR as well. Although the magnitude of the sensitivity to ICL and the combined sensitivity to both ICL and IR in hSNM1B-depleted cells was reminiscent of FA cells, FANCD2 monoubiquitination occurred normally in these cells in response to DNA damage. These results identify a new component in the mammalian response to DNA damage induced by ICL and IR, hSNM1B, and suggest that it acts downstream of the FA core complex in the DNA damage response pathway.
Results

Identification of hSNM1B
A genomic clone providing a partial sequence of hSNM1B was previously identified based on its sequence similarity to yeast PSO2 and human SNM1 (Dronkert et al., 2000) . We used this partial sequence as a template in an NCBI nucleotide database search and identified numerous cDNA clones with a perfect match. Several of these clones encode a complete open reading frame (ORF) of 532 aa, suggesting that they represent full-length copies of hSNM1B. Alignment of one of these cDNA sequences (accession number AK024060) with the sequence of the genomic clone identified before (accession number AL137856) suggested that the hSNM1B protein is encoded by four exons (Figure 1) , spanning a region of approximately 7 kb on chromosome 1p13.1-13.3.
Similarity to PSO2 is restricted to the amino-terminal part of the deduced amino-acid sequence of hSNM1B with 33% identity between amino acids 11 and 214 ( Figure 1 ). RT-PCR experiments confirmed the existence of transcripts corresponding to the full-length hSNM1B cDNA, and also revealed the existence of an unexpected shorter hSNM1B transcript, lacking exon 2 (data not shown). Translation of this shorter transcript is predicted to result in protein truncation after 72 aa, but other partial proteins could be generated if translation were to initiate at one of several potential hSNM1B functions in DNA damage response I Demuth et al start sites in exon 4. These shorter isoforms would lack the PSO2 homology domain. hSNM1B cDNAs lacking exon 2 are present in the NCBI sequence database, suggesting that the corresponding transcript, while very rare, is a legitimate product of this gene.
In order to assay expression of the predicted hSNM1B protein, we raised antibodies against a 16 aa peptide corresponding to the C-terminus of hSNM1B (Ab-1) and against a GST-hSNM1B fusion protein, containing the last 190 aa of hSNM1B (VMRC10). No proteins migrating at the predicted size for hSNM1B were detected in immunoblots from HeLa cell lysates or immunoprecipitates, despite the presence of hSNM1B transcripts in these cells detectable by RT-PCR. Interestingly, the yeast homolog PSO2, the human and mouse SNM1 and the human SNM1C/ARTEMIS are all expressed at very low levels, and the failure to detect hSNM1B raises the possibility that this is a common feature of proteins of the SNM1B family (Richter et al., 1992; Dronkert et al., 2000; Moshous et al., 2001) .
In order to confirm that the putative full-length hSNM1B transcript could encode a protein detectable with the antibody reagents generated, HeLa cells were transiently transfected with an hSNM1B expression construct (pCMV-hSNM1B), containing the hSNM1B ORF fused in-frame to a c-myc tag on its 5 0 -end. Transiently expressed hSNM1B was immunoprecipitated using Ab-1 and successfully detected in immunoblots with antibody VMRC10 at the predicted size of approximately 60 kDa ( Figure 2a , lanes 1 and 3).
siRNA-induced depletion of hSNM1B
To determine whether the hSNM1B gene is involved in the cellular DNA damage response, we attempted to modulate hSNM1B expression levels using RNA interference. Since endogenous hSNM1B protein was not detectable by immunoblot, this approach could not be used to validate hSNM1B reduction. Instead, HeLa cells were cotransfected with a plasmid expressing c-myctagged hSNM1B, together with the hSNM1B siRNA or control siRNAs. Western blot analysis of transiently expressed hSNM1B immunoprecipitated with antibody Ab-1 and detected with a biotinylated anti-c-myc antibody demonstrated that hSNM1B was well expressed in cells cotransfected with control siRNAs specific for either luciferase GL2 or FANCA (Figure 2a, lanes 1 and 3) . In contrast, hSNM1B siRNA specifically inhibited hSNM1B expression from the plasmid, validating the functionality of the siRNA ( Figure 2a, lane 2) . In addition to this indirect measure of the effect of the hSNM1B siRNA, a direct assessment of the effect of siRNA treatment on the relative level of endogenous hSNM1B mRNA was performed by RT-PCR. Transfection of the hSNM1B siRNA resulted in reduced hSNM1B mRNA levels, as indicated by a relative weak RT-PCR signal compared to controltransfected cells (Figure 2b, lanes 1 and 3) . Expression of an unrelated housekeeping gene, GAPDH, was not affected by transfection of either siRNAs (Figure 2b ).
hSNM1B depletion confers sensitivity to MMC and cisplatin
Mutations in the yeast PSO2 gene confer sensitivity to ICL-inducing agents. To evaluate the involvement of hSNM1B in the mammalian response to this class of chemicals, we treated hSNM1B siRNA-transfected HeLa cells with increasing concentrations of MMC and assayed their ability to form colonies relative to control cells. The hSNM1B depletion resulted in increased MMC sensitivity in five independent experiments, of which one representative is shown in Figure 3a . This sensitivity was comparable to that observed when HeLa cells were treated with an siRNA specific for FANCD2 (Figure 3a and d) , a gene known to confer MMC sensitivity when mutated in cells from FA patients.
To investigate if the ICL-sensitive phenotype was restricted to MMC, as has been reported for mouse ES cells mutated in the related mSNM1 gene (Dronkert , 2000) , the sensitivity of hSNM1B-depleted HeLa cells to cisplatin, another ICL-inducing chemical, was assessed. As indicated in Figure 3b , hSNM1B knockdown also increased sensitivity to cisplatin as well as MMC, suggesting a general involvement of hSNM1B in the response to ICL, although specific sensitivities to different agents may vary.
hSNM1B-depleted cells are radiosensitive
Cell lines generated from patients with mutations in the hSNM1C/ARTEMIS gene are radiosensitive, and FA cells are also reported to be moderately radiosensitive. Accordingly, the sensitivity of hSNM1B-depleted cells to IR was determined. In colony survival assays, these cells displayed significantly increased radiosensitivity, which was indistinguishable from that of cells treated with siRNAs specific for 53BP1, a known component of the mammalian DSB response pathway (Figures 3c and  e) (DiTullio et al., 2002) .
hSNM1B is required to maintain chromosome stability
The increased sensitivity of the hSNM1B-depleted cells to multiple DNA-damaging agents raised the question as to whether this phenotype is associated with chromosome instability. Chromosome instability in hSNM1B siRNA-transfected HeLa cells was analysed in metaphases after treatment with MMC. An elevated rate of chromosome breakage for hSNM1B-depleted cells was observed by counting metaphases containing at least one tri-or quadriradial exchange figure, compared to control cells (P ¼ 0.0098). There was no significant difference in the number of aberrant metaphases between cells treated with either hSNM1B siRNA or FANCA siRNA (P ¼ 0.522), the latter serving as a positive control (Table 1) .
Monoubiquitination of FANCD2 is not affected by hSNM1B depletion
Since the phenotype of hSNM1B knockdown cells in response to DNA damage, as reported here, is similar to Figure 4 . Monoubiquitination of FANCD2 in response to either MMC or IR was not diminished in cells treated with hSNM1B siRNA (Figure 4 ).
Discussion
hSNM1B is a previously uncharacterized member of a family of mammalian proteins displaying significant primary sequence similarity to the product of the yeast gene PSO2. Although a number of databases implicate hSNM1B as being involved in DNA repair, there are, in fact, no direct functional data to support this claim, only the suggestive evidence of sequence similarity with PSO2. In the current study, RNA interference was used to deplete human cells of hSNM1B and this treatment resulted in increased sensitivity to ICL-inducing agents such as MMC. This sensitivity was indistinguishable from control cells treated with siRNAs specific for the FANCD2 gene, a gene known to confer MMC sensitivity when mutated, underlining the significance of hSNM1B in the cellular response to MMC. There are at least three orthologs of the yeast PSO2 gene in humans: hSNM1, hSNM1B and hSNM1C/ ARTEMIS. With the results of the current study on hSNM1B, a role in the cellular response to DNA damage has been demonstrated by functional studies for all three PSO2 orthologs. Although deficiency for any one of these three proteins results in hypersensitivity to DNA-damaging agents, the range of agents to which cells become sensitive varies with the particular gene that is affected. A knockout of the murine SNM1 gene renders ES cells moderately sensitive to ICL induced by MMC. However, this effect appears to be somewhat specific to MMC, as sensitivity to other crosslinking agents, such as cisplatin and melphalan, is not increased in these knockouts (Dronkert et al., 2000) . In contrast, hSNM1C/ARTEMIS functions in the pathway for DSB repair. Inactivating mutations in human and mouse SNM1C/ARTEMIS result in hypersensitivity to IR but not to ICL-inducing agents (Callebaut et al., 2002; Rooney et al., 2002) . Our studies of hSNM1B suggest a more general role for its gene product. Depletion of hSNM1B by RNA interference induced sensitivity to both MMC and cisplatin as well as to IR. The HeLa cells, in which knockdowns were performed, were relatively resistant to the cell killing effects of these agents, making it difficult to compare directly results of hSNM1B depletion with null cells for established genes in DNA damage response pathways. However, inclusion of siRNA controls for FANCD2 and 53BP1 in the same experiments as hSNM1B provides some measure of the degree of sensitization induced. Thus, despite their likely common evolutionary origin and sequence similarity, the three mammalian SNM1 genes are unlikely to be redundant in their functions.
Although the precise mechanism of ICL repair in mammalian cells is unknown, sensitivity to both ICLs and IR is reported for a group of genes that are important for recombinational repair of DSB. The appearance of DSB as an intermediate in the ICL repair has been documented for S. cerevisiae (Jachymczyk et al., 1981; Magana-Schwencke et al., 1982; McHugh et al., 2000) , and there is clear evidence that DSBs occur during ICL repair in mammalian cells as well (De Silva et al., 2000; Rothfuss and Grompe, 2004) . hSNM1C/ ARTEMIS functions in the NHEJ pathway of DSB repair, where it complexes with DNA-PK CS and processes 5 0 and 3 0 overhangs (Ma et al., 2002) . mSNM1 À/À ES cells exhibit moderate MMC sensitivity and no radiosensitivity. Nonetheless, a function in DSB repair is not completely excluded because it is not clear if these mSNM1 À/À ES cells represent a null phenotype (Dronkert et al., 2000) . In addition, the fraction of human cells containing hSNM1 foci increases dramatically following exposure to IR, and in these foci hSNM1 is reported to colocalize with 53BP1 (Richie et al., 2002) , a molecule clearly involved in the signaling of DSBs. Therefore, there is at least circumstantial evidence that all three PSO2 homologs, hSNM1, SNM1B and hSNM1C/ARTEMIS, may be involved in DSB repair.
In the studies shown here, depletion of hSNM1B resulted in cellular hypersensitivity to different DNA interstrand crosslinking agents and IR. Whether these cellular phenotypes arise because hSNM1B is directly involved in the repair of these types of induced DNA damage or plays a more indirect role, facilitating the formation of repair complexes or signaling the presence of particular types of DNA damage, remains to be resolved. Perhaps the closest phenotype to that of hSNM1B knockdown cells occurs in cells derived from patients with FA, particularly in terms of their sensitivity to ICL-inducing agents in survival and chromosome stability. There are also several reports of increased radiosensitivity in FA cells (Carreau et al., 1999; Garcia-Higuera et al., 2001; Gatti, 2001; Digweed et al., 2002) . Given this similarity, we considered the possibility that hSNM1B might function in the FA/ BRCA pathway. The FA proteins A, C, E, F, G and L are required for normal monoubiquitination of FANCD2 in response to DNA damage, a key downstream event in the FA/BRCA pathway. In the current study, hSNM1B depletion did not affect FANCD2 monoubiquitination in response to either MMC or IR. Recently, two new FA complementation groups have been described. Cells of complementation group FA-I are deficient in FANCD2 monoubiquitination, whereas cells of the second new group, FA-K, are proficient for that step (Levitus et al., 2003) . Thus, proficiency of FANCD2 monoubiquitination in hSNM1B knockdown cells does not necessarily rule out hSNM1B as an FA hSNM1B functions in DNA damage response I Demuth et al gene, but suggests a function downstream of the core complex.
In summary, our results demonstrate the involvement of hSNM1B in cellular DNA damage response. While the exact biochemical function of hSNM1 remains to be elucidated, the sensitivity of hSNM1B knockdown cells to DSB, in addition to their ICL sensitivity, suggests that hSNM1B functions in a later step of the ICL repair, probably after DSB formation. This would be in agreement with a late role in ICL repair demonstrated for the yeast homolog PSO2. The FA-like phenotype of hSNM1B knockdown cells raises the possibility of involvement of hSNM1B in the FANC/BRCA pathway, suggesting hSNM1B as a candidate for one of the remaining FA genes not required for FANCD2 monoubiquitination.
Materials and methods
Cell lines and culture
HeLa cells and SV40-transformed fibroblasts GM0637, GM06914C (FA-A) and GM 16633A (FA-D2) were grown in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Rockville, MD, USA) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies). Cells were grown in a humidified 5% CO 2 incubator at 371C.
hSNM1B expression construct
The hSNM1B ORF was amplified from total RNA extracted from HeLa cells. The resulting RT-PCR product was cloned into the plasmid pT7T319U (Pharmacia). In a second PCR using pT7T319U-hSNM1B as a template, the hSNM1B ORF was amplified to introduce PstI restriction sites at both termini of the product, followed by cloning into the PstI site of the expression plasmid pCMV-Tag3B (Stratagene), in-frame with a c-myc tag on its 5 0 -end.
siRNAs and transfections
siRNA duplexes were designed as described (Elbashir et al., 2002) . siRNAs specific for hSNM1B (GAAGCUGCCCACCAGAUUGdTdT), FANCA and luciferase GL2 (control siRNA) were purchased from Dharmacon Research (Lafayette, CO, USA). siRNAs for FANCD2 (CACCUCAUACU-GUUACUGCUU) and 53BP1 were produced using the Silencer siRNA Construction Kit (Ambion, Austin, TX, USA). FANCA and 53BP1 siRNA sequences have been described previously (DiTullio et al., 2002; Bruun et al., 2003) . A total of 3 Â 10 4 HeLa cells in 500 ml DMEM without antibiotics were plated 24 h before transfection in the wells of a 24-well plate. A 3.7 ml portion of the siRNA duplexes (20 mM) was diluted in Opti-MEM1 medium (Life Technologies) to a final volume of 50 ml. In a separate tube, 3 ml of Oligofectamine transfection reagent (Invitrogen, Carlsbad, CA, USA) was mixed with 12 ml of Opti-MEM and incubated for 5 min at room temperature. The diluted siRNAs were combined with the oligofectamine mixture, incubated for 20 min at room temperature and then added to the cells without changing the media. After 6 h incubation at 371C, the transfection medium was replaced by DMEM without antibiotics. The medium was changed the next day (DMEM þ antibiotics) and cells were used for experiments 66 h after transfection start.
For plasmid/siRNA cotransfection, 1.75 Â 10 6 HeLa cells were plated in 10 cm dishes. Transfection of 6 mg plasmid and 28 ml siRNA (20 mM) was carried out the next day using 9 ml Lipofectamine (Invitrogen). After 4 h, transfection medium was replaced by DMEM and cells were assayed for protein expression 48 h after transfection start.
For detection of FANCD2 monoubiquitination, 1.5 Â 10 5 GM0637 cells were plated in 800 ml DMEM without antibiotics 24 h before transfection in the wells of a six-well plate. In all, 7.4 ml of the siRNA duplexes (20 mM) was diluted in Opti-MEM1 medium (Life Technologies) to a final volume of 185 ml. In a separate tube, 3 ml of Oligofectamine transfection reagent (Invitrogen) was mixed with 12 ml of Opti-MEM and incubated for 5 min at room temperature. The diluted siRNAs were combined with the oligofectamine mixture, incubated for 20 min at room temperature and then added to the cells without changing the media. After 6 h incubation at 371C, the transfection medium was replaced by DMEM without antibiotics. At 42 h after transfection, cells were treated for 24 h with 40 ng/ml MMC (Sigma-Aldrich, St Louis, MO, USA) or irradiated 54 h after transfection with 12 Gy using a JL Shepherd Mark I Model 22 cesium source (San Fernando, CA, USA). Immunoblotting was performed 66 h after transfection as described below.
Colony survival assays following siRNA transfection
The sensitivity of cells to increasing concentrations of DNAdamaging agents was determined by measuring their ability to form colonies. At 66 h after transfection, cells were trypsinized and plated at a density of 500 cells/100 mm tissue culture dish. At 4 h after plating, MMC or cisplatin (Sigma-Aldrich) was added to the final concentrations (in duplicates, and triplicates for untreated cells). After 1 h, the drug-containing media were removed and cells were washed twice with PBS, followed by addition of fresh media. To determine IR sensitivity, cells were irradiated before plating in 100 mm dishes. After 10-12 days incubation, colonies were fixed, stained and counted. Survival assays for hSNM1B siRNA-and control siRNAtreated cells were repeated five times (MMC), four times (IR) or two times (cisplatin). All other experiments were repeated at least two times.
Chromosome breakage analysis
HeLa cells were transfected with siRNAs as described. At 42 h after transfection, cells were treated for 24 h with 60 ng MMC/ ml. Colcemid was added for the last 2 h of incubation. Cells were trypsinized and treated with hypotonic KCl solution (75 mM) for 15 min and subsequently fixed three times with icecold methanol : glacial acetic acid (3 : 1). Cells were transferred to glass slides and stained with 10% Giemsa solution for 10 min. A total of 100 metaphases cells/sample were examined for chromatid-type interchange aberrations and scored as aberrant when showing at least one triradial, quadriradial or other type of interchange. Statistical analysis was performed using w 2 test.
Antibodies and immunoblotting
Antibodies were generated against a synthetic peptide corresponding to the C-terminal 16 aa of hSNM1B (Ab-1, Pineda hSNM1B functions in DNA damage response I Demuth et al Antibody Service, Berlin, Germany). A second antibody was raised against a bacterially expressed recombinant protein consisting of the C-terminal 190 aa of hSNM1B fused to GST (VMRC10, Cocalico Biologicals Inc., Reamstown, PA, USA). Polyclonal Nibrin/p95 (NB100-143) and FANCD2 (NB 100-182) antibodies were purchased from Novus-Biologicals (Littleton, CO, USA). Monoclonal antibodies against 53BP1 were provided by Thanos Halazonetis (Wistar Institute, Philadelphia, PA, USA) and a biotinylated version of monoclonal anti-c-Myc was purchased from Sigma (B7554). Cell extracts were prepared as described (Cerosaletti and Concannon, 2003) . Briefly, total cell lysates were prepared at a final concentration of 10 4 cells/ml. Lysates (10 5 cells) were electrophoresed using the NuPage system (Invitrogen) in 3-8% gradient Tris acetate gels. Following electrophoresis, proteins were transferred to Immobilon P nylon membranes (Millipore Corp., Bedford, MA, USA). Membranes were blocked for at least 1 h in 10% non-fat milk in Tris-buffered saline, pH 7.6, with 0.1% Tween 20 (TBS-T) and incubation with primary and secondary antibodies was performed in 5% non-fat milk in TBS-T. All washing steps were carried out using TBS-T. Primary antibodies were detected with horseradish peroxidaseconjugated goat anti-rabbit IgG (BD Pharmingen, San Diego, CA, USA) or streptavidin horseradish peroxidase conjugate (Amersham, Uppsala, Sweden). Chemiluminescence was developed using Western Lightning (PerkinElmer Life Sciences, Boston, MA, USA).
Immunoprecipitates were prepared by lysing 10 7 cells in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.3% Triton X-100 and a protease inhibitor mixture (Roche Applied Science). Lysates were immunoprecipitated with hSNM1B antibody (Ab-1) and Dynabeads Protein G (Dynal Biotech ASA, Oslo, Norway) for 2 h. Immunoprecipitates were washed with lysis buffer four times and eluted from the beads by boiling for 5 min. Immunoblotting was performed as described.
RT-PCR
Total RNA was extracted using Trizol (Invitrogen) followed by DNAse I digestion. RNA was reverse transcribed using random hexamer primers and a 929 bp hSNM1B product was amplified using primers 5 0 -CTAAGCAATGGATCCAAGCC and 5 0 -CTTGGCCTTCTTTGAGTCTC. The 431 bp GAPDH product was generated using primers 5 0 -ACCACAGTC CATGCCATCAC and 5 0 -TCCACCACCCTGTTGCTGTA.
